Peter Barker

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

Eugene R. Bleecker, J. Mark FitzGerald, Pascal Chanez et al. · The Lancet · 2016 · 1.4K citations

Pharmacy, Pharmacology, Pharmacotherapy +13

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

J. Mark FitzGerald, Eugene R. Bleecker, Parameswaran Nair et al. · The Lancet · 2016 · 1.4K citations

Pharmacy, Immunology, Pharmacology +17

Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

Parameswaran Nair, Sally E. Wenzel, Klaus F. Rabe et al. · New England Journal of Medicine · 2017 · 1K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain

William D. Chey, Lynn R. Webster, Mark Sostek et al. · New England Journal of Medicine · 2014 · 330 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

William W. Busse, Eugene R. Bleecker, J Mark FitzGerald et al. · The Lancet Respiratory Medicine · 2018 · 311 citations

Pharmacy, Pharmacology, Pharmacotherapy +6